12 Best IPO Stocks to Buy in 2025

Page 2 of 11

10. Apogee Therapeutics Inc. (NASDAQ:APGE)

Average Upside Potential as of March 21: 121.19%

Number of Hedge Fund Holders: 31

Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that develops extended half-life monoclonal antibody therapies for inflammatory and immunological diseases. These include atopic dermatitis, asthma, and COPD (Chronic Obstructive Pulmonary Disease).

The company is prioritizing the development of APG279, which is a combination therapy for atopic dermatitis (AD) and other inflammatory diseases. This therapy combines APG777 and APG990, and targets different inflammatory pathways for potentially enhanced efficacy. Crucial to this is APG990, which showed an approximate 60-day half-life in Phase 1 trials. This supports the possibility of dosing APG279 only 2-4 times a year via a single 2mL injection.

The Phase 1 trials of APG990 showed strong tolerability, with no serious adverse events and only mild side effects, like headaches, in a small percentage of patients. Preclinical studies showed no safety concerns when combining APG777 and APG990. These results pave the way for Phase 1b head-to-head trial against DUPIXENT in 2025, with data expected in H2 2026. The company has $731.1 million in cash reserves, which is projected to fund operations into Q1 2028.

Page 2 of 11